Is There a Vaccine for Andes Virus? What Current Hantavirus Research Tells Us

There is no approved Andes virus vaccine yet, but DNA and mRNA-based vaccine research is moving the field forward.

Introduction

The recent Andes virus outbreak has raised a natural question: Do we have a vaccine? The answer is: not yet. According to the CDC, there is currently no specific antiviral treatment or vaccine for Andes virus. Care is focused on early recognition, supportive treatment, and careful management of symptoms.

That gap is important because Andes virus can cause hantavirus pulmonary syndrome, a severe disease that affects the lungs. Although the disease is rare, it can be deadly. This is exactly why vaccine research for rare but high-consequence viruses matters. We do not only need vaccines for common infections—we also need platforms that can respond to unusual pathogens before they cause larger emergencies.

What vaccine research exists?

One encouraging area is DNA vaccine research. A Phase 1 clinical study tested an Andes virus DNA vaccine delivered by needle-free injection in healthy adults. The study reported that the vaccine was generally safe and induced a durable immune response, with several vaccine groups reaching at least 80% seropositivity by day 197, sustained through day 337.

Scientists are also studying vaccines for other hantaviruses. A 2024 npj Vaccines Phase 1 study evaluated Hantaan and Puumala virus DNA vaccines, which target hantaviruses more common in Asia and Europe. The study tested needle-free delivery of DNA vaccines encoding viral envelope glycoproteins, important targets for neutralizing antibodies.

Another important direction is mRNA-LNP vaccine technology, the same broad platform concept used successfully during the COVID-19 pandemic. A 2026 Nature Communications study tested DNA and mRNA-LNP vaccines encoding a prefusion-stabilized Hantaan virus glycoprotein in mice. Both vaccine formats generated strong neutralizing antibody responses and protected mice against high-dose Hantaan virus challenge; the mRNA-LNP version also worked well as a booster after prior inactivated vaccine priming.

Does this mean a vaccine is ready soon?

Not immediately. Hantavirus vaccine development faces several challenges. Hantaviruses are diverse, different viruses circulate in different regions, and the number of human cases is relatively small compared with diseases like influenza or COVID-19. That makes large clinical trials difficult. Also, a vaccine against one hantavirus may not automatically protect against all others.

Still, the progress is real. DNA vaccines, mRNA vaccines, glycoprotein immunogen design, and antibody-based approaches are giving researchers better tools than before. Recent scientific reviews also note that active research includes glycoprotein-based DNA and mRNA vaccines, broad-spectrum antiviral candidates, and antibody preparations.

Why vaccine platforms matter

The Andes virus outbreak shows why vaccine platforms are so important. Traditional vaccine development can be slow, especially for rare diseases with limited commercial markets. Platform technologies—such as DNA and mRNA—can make it faster to design, manufacture, and test vaccine candidates once scientists identify the right viral antigen.

For Yes2Vaccines, this is a key educational point: vaccines are not only a response to today’s outbreak. They are part of long-term preparedness. The best time to develop vaccines for rare but dangerous pathogens is before they appear in headlines.

Take-home message

There is no approved Andes virus vaccine today, but the science is advancing. DNA and mRNA vaccine platforms could help close the preparedness gap for hantaviruses and other rare emerging infections. The current outbreak should encourage calm public education, stronger surveillance, and sustained investment in vaccine research—not fear.